Hofmann, Francesco and Garcia-Echeverria, Carlos (2005) Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discovery Today, 10 (15). pp. 1041-1047. ISSN 1359-6446

Abstract

Clear links between cancer and cellular signaling triggered by the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and its cognate ligands (IGF-I and IGF-II) have been reported throughout the past two decades. Experimental results suggest that the pharmaceutical targeting of this signaling pathway could be beneficial for the treatment of cancer. Here, more recent advances towards potentially clinically viable strategies to interfere with the function of IGF-IR will be discussed.

Item Type:	Article
Related URLs:	http://www.ncbi.nlm.nih.gov/sites/entrez... doi:10.1016/S1359-6446(05)03512-9
Additional Information:	author can archive post-print (ie final draft post-refereeing); Publisher's version/PDF cannot be used
Keywords:	IGF-IR; Growth factor; Conformational change; Antibodies; Kinase inhibitor; Drug Discovery
Related URLs:	http://www.ncbi.nlm.nih.gov/sites/entrez... doi:10.1016/S1359-6446(05)03512-9
Date Deposited:	14 Dec 2009 13:58
Last Modified:	31 Jan 2013 01:14
URI:	https://oak.novartis.com/id/eprint/521